Introduction {#sec1-2048004020929235}
============

Atherosclerosis is now considered to be primarily a progressive inflammatory disease. Innate immune responses are activated during the development of atherosclerotic plaques, leading to the secretion of interleukin (IL)-1α and the activation of the inflammasome complex, which produces activated cytokines IL-1β and IL-18.^[@bibr1-2048004020929235]^ Levels of IL-1β in atherosclerosis have been correlated to disease severity, with circulating IL-1β producing increases in reactive oxygen species, matrix metalloproteinases,^[@bibr2-2048004020929235]^ inflammatory cytokines and activated T-cells, resulting in disruption of the extracellular matrix.

Although atherosclerosis involves chronic inflammation at every stage, there are no approved therapies to treat this inflammatory component. Canakinumab is a monoclonal antibody against IL-1β approved for auto-inflammatory disorders, which was evaluated in CANTOS.^[@bibr3-2048004020929235]^ CANTOS showed that canakinumab reduces the risk of secondary cardiovascular events, representing conclusive evidence that targeting the inflammatory processes of atherosclerosis alone improves outcomes. An increase in serious and fatal infections contributed to the regulatory rejection of canakinumab for use in cardiovascular disease.

Statin medications, which inhibit cholesterol synthesis, have also been shown to possess immunomodulatory and anti-inflammatory properties. Statins have anti-inflammatory effects on the vascular endothelium via upregulation of endothelial nitric oxide synthase, increasing nitric oxide (NO) production. Statins also decrease the production of superoxide radicals and other reactive oxygen species via reduction of reduced nicotinamide adenine dinucleotide phosphate oxidase activity.^[@bibr4-2048004020929235]^

Established biomarkers used to assess cardiovascular risk include total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides. Plasma levels of apolipoprotein B (ApoB), which is present in very low density lipoprotein, LDL and IDL particles, can also be measured to provide an indication of atherogenic cholesterol. The ratio of ApoB to ApoA1 can be used as a risk marker,^[@bibr5-2048004020929235]^ as this ratio reflects the balance between pro- and anti-atherogenic lipoproteins.

C-reactive protein (CRP) is the most widely investigated inflammatory marker examined in the context of atherosclerotic disease. It has been adopted as a biomarker of inflammation with applications in cancer, infections, chronic inflammatory diseases, diabetes and cardiovascular diseases. It is primarily produced by hepatocytes in response to secretion of IL-6 via upregulation of transcription factors CCAAT/enhancer-binding protein β (C/EBPβ) and C/EBPδ; however, it is also produced by endothelial cells, lymphocytes, smooth muscle cells and macrophages in atherosclerotic lesions.^[@bibr6-2048004020929235]^ IL-1β and tumour necrosis factor can also increase the transcription rate of genes encoding CRP.^[@bibr7-2048004020929235]^

An individual participant meta-analysis of 54 studies involving 160,309 subjects without cardiovascular disease(CVD) showed that CRP levels were linearly associated with coronary heart disease, ischaemic stroke and cardiovascular mortality.^[@bibr8-2048004020929235]^ However, correction for conventional risk factors and baseline fibrinogen levels considerably weakened the association between CRP levels and coronary heart disease and eliminated the association between CRP levels and stroke. This suggests that CRP should not be used to assess risk independent of validated risk factors but should be used as an additional tool to identify those with prevalent atherosclerosis.

To date, a comprehensive evaluation of the association between changes in CRP levels following anti-inflammatory treatment and cardiovascular outcomes has not been conducted. This research aimed to characterise the relationship between achieved CRP and incidence of major adverse cardiovascular events (MACEs).

Methods {#sec2-2048004020929235}
=======

Literature search strategy {#sec3-2048004020929235}
--------------------------

Inclusion criteria for the systematic review and meta-analysis were randomised controlled trials published in English that measured CRP levels before and after treatment with an anti-inflammatory therapy for at least 24 weeks and reported MACE ([Table 1](#table1-2048004020929235){ref-type="table"}). Studies were excluded where the change in CRP could not be determined, the chosen therapy did not exert anti-inflammatory effects and significant comorbidities were present, such as heart or kidney failure. Placebo-controlled study designs were included in the meta-analysis, with studies comparing two or more interventions included in a narrative synthesis. Placebo-controlled studies that also recorded changes in LDL and triglycerides were included in a prespecified meta-regression.

###### 

PICOS eligibility criteria.

![](10.1177_2048004020929235-table1)

  -------------- --------------------------------------------------------
  Population     Those at risk of cardiovascular disease
  Intervention   Statin or anti-inflammatory therapy that decreases CRP
  Comparison     Placebo or statin/ anti-inflammatory comparator
  Outcome        Major adverse cardiovascular events
  Study design   Randomised controlled trials
  -------------- --------------------------------------------------------

PubMed, Medline, Embase and Google Scholar were searched using a combination of the following keywords: (statin or anti-inflammatory) and (cardiovascular disease or atherosclerosis) and (CRP or hsCRP or C-reactive protein) and (Trial or RCT) and (MACE or cardiovascular events or mortality or outcomes or stroke or angina or myocardial infarction). The search was carried out between the 21 and 23 April 2019. The reference lists of each selected study were also consulted to identify further studies. One reviewer screened and selected articles for further review. The titles and abstracts were reviewed to assess whether the study met the prespecified criteria, with relevant articles then selected for a full-text review.

Quality and risk-of-bias assessments {#sec4-2048004020929235}
------------------------------------

The quality of each study selected for inclusion was assessed using the quality assessment tool for controlled intervention studies published by the National Heart, Lung, and Blood Institute.^[@bibr9-2048004020929235]^ The final rating was determined by an overall judgement of the relevance of any issues to the validity of the results, and each study was given a grade of 'good', 'fair' or 'poor', which also took into account factors such as the applicability of the question to the study being assessed, and the impact of the quality of reporting on the information available for the quality assessment. Studies receiving a rating of 'poor' were to be excluded from the meta-analysis. The revised Cochrane risk-of-bias tool (RoB2) for randomised trials was used to assess the risk of bias of each study selected for inclusion.

Data extraction {#sec5-2048004020929235}
---------------

The median baseline CRP, median achieved CRP, median change from baseline (%) and the percentage difference in CRP change from baseline between treatment groups reported in each study publication were collated. Incidence of MACE, which was defined as nonfatal myocardial infarction, nonfatal stroke, cardiovascular mortality, unstable angina requiring hospitalisation and urgent revascularisation, was also extracted for both the control and intervention groups and divided by the number of participants in each group to find the event rate. The between-group percentage differences in MACE incidence and follow-up duration were also recorded.

In order to carry out a meta-regression examining the influence of conventional risk factors LDL and triglycerides on cardiovascular outcomes, mean baseline LDL, mean achieved LDL, percentage change from baseline and between-group difference in achieved LDL were recorded. The same values were recorded for the triglyceride measurements.

Data synthesis {#sec6-2048004020929235}
--------------

Due to methodological differences in the studies included in this review, the data collected were synthesised narratively, with a subset of the studies included in a meta-analysis. The data collected were assessed in turn in order to determine the extent of a relationship between a reduction in CRP and event risk. For the meta-analysis, an initial descriptive analysis of effect size, a forest plot illustrating the effect summary and a scatter plot of percentage change in CRP vs. percentage change in MACE were created using Microsoft Excel version 14.7.7. To calculate the effect summary and to graph the forest plot in Excel, the method described by Neyeloff et al. was employed.^[@bibr10-2048004020929235]^ Heterogeneity between studies was measured using the *I*^2^ statistic (*I*^2^ = 100% × (*Q* --df)/*Q*), where *Q* is Cochran's heterogeneity statistic. Due to high heterogeneity in the study populations and treatments (*I*^2^ = 81%), a random-effects model was applied. A meta-regression to examine the influence of LDL and triglyceride reduction on MACE, and the association between LDL and CRP reduction, was carried out using the metareg command in Stata version 15.1.

Results {#sec9-2048004020929235}
=======

Literature search {#sec10-2048004020929235}
-----------------

A total of 4331 articles were retrieved from PubMed, Medline, Embase and Google Scholar ([Figure 1](#fig1-2048004020929235){ref-type="fig"}). After removing duplicates (Medline/Embase) and applying filters for the English language and clinical trials (PubMed and Medline/Embase), 1793 titles and abstracts were reviewed. Five articles were identified from reference lists. Of 285 full-text articles assessed, 269 were excluded, as they did not measure CRP before and after treatment, MACE incidence was not recorded or another aspect of the eligibility criteria was not met. Ultimately, 15 studies were eligible for inclusion in the narrative review, nine studies were included in the meta-analysis and six studies met the criteria for the meta-regression.

![PRISMA flow diagram: the literature search and screening process.](10.1177_2048004020929235-fig1){#fig1-2048004020929235}

Quality and risk-of-bias assessments {#sec11-2048004020929235}
------------------------------------

Of the 15 studies included in this review, 12 received a 'good' rating and 3 received a 'fair' rating. No studies received a 'poor' rating ([Appendix 1](#app1){ref-type="app"}). No studies were associated with a high risk of bias in any domain of the Cochrane risk-of-bias tool ([Appendix 2](#app2){ref-type="app"}).

Characteristics of the included studies {#sec12-2048004020929235}
---------------------------------------

Of the 15 studies included, six studies used an active comparator study design. Wang et al. compared ezetimibe 10 mg/day and rosuvastatin 10 mg/day to rosuvastatin 10 mg/day alone;^[@bibr11-2048004020929235]^ the SATURN study compared atorvastatin 80 mg to rosuvastatin 40 mg;^[@bibr12-2048004020929235]^ the CHERRY study compared pitavastatin 4 mg and eicosapentaenoic acid 1800 mg to pitavastatin 4 mg alone;^[@bibr13-2048004020929235]^ Im et al. compared atorvastatin 40 mg to pravastatin 20 mg;^[@bibr14-2048004020929235]^ the REAL-CAD study compared pitavastatin 4 mg to pitavastatin 1 mg;^[@bibr15-2048004020929235]^ the REDUCE-IT study evaluated icosapent ethyl in addition to statin therapy in comparison to statin therapy alone.^[@bibr16-2048004020929235]^

The remaining nine studies compared a single intervention to placebo, with seven studies evaluating statin therapy,^[@bibr17-2048004020929235][@bibr18-2048004020929235][@bibr19-2048004020929235][@bibr20-2048004020929235][@bibr21-2048004020929235][@bibr22-2048004020929235]--[@bibr23-2048004020929235]^ one study evaluating canakinumab^[@bibr3-2048004020929235]^ and the SUSTAIN/ASSURE studies evaluating RVX-208, which is an inhibitor of bromo- and extra-terminal proteins that regulate ApoA1.^[@bibr24-2048004020929235]^ Six placebo-controlled studies^[@bibr17-2048004020929235],[@bibr19-2048004020929235][@bibr20-2048004020929235][@bibr21-2048004020929235][@bibr22-2048004020929235]--[@bibr23-2048004020929235]^ were included in the meta-regression, with TRACE-RA and HOPE-3 excluded due to missing LDL and triglyceride data, and CANTOS excluded as canakinumab has no effect on lipid levels ([Appendix 3](#app3){ref-type="app"}).

Association between CRP reduction and cardiovascular outcomes {#sec13-2048004020929235}
-------------------------------------------------------------

### Active comparator studies {#sec14-2048004020929235}

*Association is dependent on lipid lowering*: In Wang et al., CRP decreased by 66.4% in the rosuvastatin group and by 78.2% in the rosuvastatin and ezetemibe group at 12 months.^[@bibr11-2048004020929235]^ MACE incidence was 12.5% in the rosuvastatin group and 4% in the rosuvastatin and ezetimibe group. As ezetemibe does not typically decrease CRP alone,^[@bibr25-2048004020929235],[@bibr26-2048004020929235]^ the additional reduction in CRP is likely to be related to the additional reduction in LDL observed in the rosuvastatin and ezetemibe group, when compared to the rosuvastatin group (62% vs. 47%, respectively). In the REAL-CAD study, CRP levels were 14% lower in the pitavastatin 4 mg group vs. the 1 mg group, with no change from baseline observed in the 1 mg group.^[@bibr15-2048004020929235]^ A reduction in LDL of 16% from baseline in the 4 mg group and no change in the 1 mg group is likely to contribute to the difference in event rates (4.3% in the 4 mg group vs. 5.4% in the 1 mg group).

During REDUCE-IT, which evaluated the addition of icosapent ethyl 4 g/day to statin therapy, median CRP increased from 2.1 to 2.8 mg/l in the statin-only group.^[@bibr16-2048004020929235]^ In the icosapent ethyl group, median CRP decreased from 2.2 to 1.8 mg/l. MACE occurred in 22% of the statin-only group and 17.2% of the icosapent ethyl group. Icosapent ethyl has been proven to reduce triglyceride levels, which are a validated risk factor for cardiovascular disease. Specifically, follow-up triglyceride levels were 20% lower in the intervention group, which may account for the decrease in events observed.

The reduction in MACE is proportional to the reduction in CRP achieved in these studies. However, there is no evidence to suggest that the risk reduction observed in these studies is mainly due to anti-inflammatory factors, as the extent of reduction in lipid levels also correlates to clinical outcome. The results from these studies support the view that additional CRP reduction in the intervention group may be a by-product of an improvement in the patients' conditions, rather than a causal factor.

*Association is independent of lipid lowering*: Im et al. found that pravastatin 20 mg did not decrease CRP and was associated with a MACE incidence of 3.6%, whereas atorvastatin 40 mg decreased CRP by 22.2% from baseline and was associated with an event rate of 2%.^[@bibr14-2048004020929235]^ Changes in LDL were minimal, although some patients were allocated to a less intensive treatment than their typical regimen. Nevertheless, the reduction in event rates achieved in this study suggests that anti-inflammatory pleiotropic effects of statin treatment are partly attributable.

*No association between CRP reduction and cardiovascular outcomes*: In SATURN and CHERRY, no associations were found between on-treatment CRP levels and event risk. In SATURN, rosuvastatin 40 mg was significantly more effective at lowering CRP vs. atorvastatin 80 mg; however, no significant differences in MACE were found.^[@bibr12-2048004020929235]^ As SATURN was not powered to detect differences in MACE, conclusions cannot be drawn as to the presence of an association between CRP reduction and outcomes. In CHERRY, no significant between-group differences were observed for CRP reduction or MACE incidence.^[@bibr13-2048004020929235]^ Although it could be argued that a lack of additional CRP reduction is associated with a lack of additional cardiovascular risk reduction in these studies, conventional risk factors LDL and triglyceride levels also showed little change after treatment in both SATURN and CHERRY. This suggests that aspects of the design and methodology of the studies, such as prior statin treatment in both study populations and lack of statistical power, hinder the ability to rationalise the lack of between-group differences.

### Placebo-controlled studies {#sec15-2048004020929235}

Treatment with statins, canakinumab and RVX-208 decreased the incidence of MACE in every placebo-controlled study ([Figure 2](#fig2-2048004020929235){ref-type="fig"}). Each therapy decreased CRP; however, there was no correlation between the magnitude of CRP reduction achieved and the decrease in cardiovascular events between the groups in these studies (*R*^2^ = 0.082, *p* \< 0.49) ([Figure 3](#fig3-2048004020929235){ref-type="fig"}).

![Effect of treatment on cardiovascular event rates (placebo-controlled studies).](10.1177_2048004020929235-fig2){#fig2-2048004020929235}

![Association between magnitude of CRP reduction and cardiovascular event reduction (*p* \< 0.49).](10.1177_2048004020929235-fig3){#fig3-2048004020929235}

*Association is dependent on lipid lowering*: Heljić et al. evaluated simvastatin in patients with type II diabetes mellitus without CVD.^[@bibr17-2048004020929235]^ CRP decreased by 4% in the placebo group and 19% in the simvastatin 40 mg group. Moreover, 40% of patients receiving placebo experienced an event vs. 17.8% receiving statin therapy. LDL reduction was proportional to CRP reduction. This study reported the greatest between-group difference in event rates. This may be related to its small size (*n* = 95); additionally, it is not stated whether this study was powered to detect differences in clinical outcomes. In CARDS, atorvastatin 10 mg reduced event risk by 37%, CRP by 32% and LDL by 42% vs. placebo.^[@bibr22-2048004020929235]^ No significant association was found between baseline, on-treatment or change in CRP and cardiovascular risk. No evidence was found that achieving a target CRP level in addition to a target LDL level further reduced risk.

ASCOT-LLA found that statin therapy decreased MACE by 22.81% vs. placebo in hypertensive patients without elevated lipids, with CRP 25% lower in the atorvastatin group vs. placebo.^[@bibr21-2048004020929235]^ LDL levels decreased by 29% and triglycerides by 13%. Those who achieved CRP levels below the median did not have a reduced event risk when compared to those who did not achieve CRP levels below the median \[OR 0.86, 95% CI: 0.49--1.51\]. In contrast, event risk was significantly reduced in those achieving LDL below the median \[OR 0.41, 95% CI: 0.22--0.75\]. HOPE-3 also evaluated statin therapy in patients at intermediate risk without CVD.^[@bibr23-2048004020929235]^ Although a subgroup analysis based on achieved CRP was not carried out, this study found that rosuvastatin possessed similar efficacy regardless of baseline CRP level. Small reductions in CRP were achieved when compared to the 26.5% reduction in LDL (log-transformed mean difference: 0.19 mg/l). The results of these four studies suggest that in primary prevention settings, achieving lower CRP does not provide a substantial benefit on top of achieving lipid targets.

TRACE-RA evaluated statin therapy in rheumatoid arthritis (RA) patients without pre-existing CVD.^[@bibr18-2048004020929235]^ LDL and CRP levels were 34% and 28% lower in the atorvastatin 40 mg group vs. placebo, respectively. A non-significant 34% reduction in MACE was recorded. It appears that statins maintain their lipid-lowering effect in this population despite active inflammation, and although LDL levels are typically lower in RA patients (baseline LDL: 3.2 mmol/l), the 35% reduction achieved indicates that reduction of events was achieved primarily through lipid lowering.

*Association is independent of lipid lowering*: AFCAPs/TexCAPS evaluated lovastatin 20 mg vs. placebo in participants without established CVD and average LDL levels.^[@bibr20-2048004020929235]^ Lovastatin decreased CRP by 14.8% vs. no reduction, with LDL levels reduced by 25%. The reduction in CRP observed with lovastatin was not correlated to LDL or triglyceride reduction. MACE occurred in 2.94% of those receiving lovastatin vs. 4.6% receiving placebo, with stratified analyses showing that lovastatin was effective in participants who had higher than average CRP and lower than average LDL, but not in those with both lower than average LDL and CRP.

JUPITER evaluated statin therapy in those with normal LDL cholesterol levels (\<3.4 mmol/l) but elevated CRP (\>2 mg/l).^[@bibr19-2048004020929235]^ Rosuvastatin reduced CRP by 37% and LDL by 50%, which was associated with a 44% reduction in MACE. For those who achieved LDL \< 1.8 mmol/l and CRP \< 2 mg/l, MACE incidence was reduced by 65% vs. 33% in those who achieved one or neither targets.^[@bibr27-2048004020929235]^ This points towards a predictive role for achieved CRP in relation to cardiovascular risk. In CANTOS, which evaluated anti-IL-1β antibody canakinumab in participants with normal LDL, 35--40% reductions in IL-6 and CRP were observed in the 150 and 300 mg canakinumab groups with no changes in cholesterol levels, which was predictive of clinical efficacy. The extent of reduction in CRP following canakinumab was strongly correlated to cardiovascular risk reduction.^[@bibr3-2048004020929235]^

SUSTAIN/ASSURE suggested an association between CRP reduction and clinical outcomes that cannot be explained by changes in lipid levels.^[@bibr24-2048004020929235]^ Treatment with RVX-208 and placebo produced no clinically significant changes in LDL and reduced CRP by 28.4% and 22.4%, respectively. MACE incidence was 5.4% in the treatment group vs. 10.1% with placebo. A significant but modest between-group increase (7.69%) in HDL levels was observed, which could not account for the reduction in events seen in this study.^[@bibr24-2048004020929235]^ Anti-inflammatory mechanisms of RVX-208 have been proposed, which are supported by reductions in chemokine CCL18 and IL-18, by 22% and 10%, respectively, in groups treated with RVX-208.^[@bibr24-2048004020929235]^ These four studies support the view that on-treatment reductions in inflammatory markers are predictive of clinical efficacy. Although they do not demonstrate a clear relationship between magnitude of reduction in CRP and reduction in cardiovascular risk, differences in study populations and treatment regimens complicate direct comparisons.

Meta-regression {#sec16-2048004020929235}
---------------

A meta-regression of six placebo-controlled studies showed a strong correlation (adjusted *r*^2^ = 0.8, *p* \< 0.011) between changes in LDL levels and CRP levels ([Figure 4](#fig4-2048004020929235){ref-type="fig"}). When the influence of changes in LDL and triglyceride levels on the effect sizes in each study was analysed, it was found that changes in CRP accounted for 54.25% of between-study differences in event rates and that LDL and triglyceride reduction accounted for 68.35% of between-study differences in event rates, which is accordance with the fact that CRP reduction is strongly correlated to LDL reduction. CRP, LDL and triglyceride reduction accounted for 80% of between-study differences in event rates.

![Association between LDL and CRP reduction.](10.1177_2048004020929235-fig4){#fig4-2048004020929235}

Discussion {#sec17-2048004020929235}
==========

This systematic review evaluated the extent of reduction in CRP achieved by treatments for CVD and whether this correlated with improvements in outcomes in all trials that measured CRP before and after treatment and recorded incidence of adverse cardiac events. This research found that CRP reduction occurred alongside a reduction in events; however, a greater magnitude of reduction did not signify better clinical outcomes. The balance of the evidence supports the view that improvements in clinical outcomes can largely be accounted for by reduction in LDL, with CRP reduction occurring as a by-product to LDL reduction. These findings are in accordance with a meta-analysis conducted by Kinlay in 2007, which assessed the extent of the association between changes in CRP and LDL after treatment with a cholesterol-lowering therapy.^[@bibr28-2048004020929235]^ This study found a variance-adjusted correlation between change in CRP and LDL of 0.80 (*p* \< 0.001) and showed that 89--98% of CRP reduction was related to LDL reduction, with 2--11% of changes in CRP levels related to the anti-inflammatory effects of statins. This is in accordance with the strong correlation found in this review between CRP and LDL reduction ([Figure 4](#fig4-2048004020929235){ref-type="fig"}).

The conflicting evidence provided by the included studies is likely to result from differences in study populations and baseline characteristics, supporting the view that targeting CRP in entire patient populations is less effective than stratifying based on baseline CRP. In studies with no restrictions as to baseline CRP, baseline CRP is lower (e.g. 1.4 mg/l in CARDS,^[@bibr22-2048004020929235]^ 2.7 mg/l in ASCOT-LLA^[@bibr21-2048004020929235]^ and 2.0 mg/l in HOPE-3,^[@bibr23-2048004020929235]^ compared to 4.3 mg/l in JUPITER^[@bibr19-2048004020929235]^), which may explain the lack of evidence supporting cardiovascular risk reduction mediated by changes in CRP in these studies.

The CANTOS trial demonstrated that on-treatment CRP levels are effective in predicting the clinical response from anti-inflammatory therapies such as canakinumab. This reflects the fact that canakinumab treatment is intended for those with high residual inflammatory risk that is not adequately controlled by cholesterol-lowering therapies, whereas statin therapy is indicated for patients at risk of CVD regardless of their inflammation status.

Based on the results of this review, achieved CRP cannot be used as a reliable method of determining the efficacy of existing treatments for CVD. In the case of treatment strategies that solely target inflammation, the existence of a dose--response relationship for CRP reduction in CANTOS (26%, 37% and 41% in the 50, 150 and 300 mg treatment groups, respectively) did not directly translate to improved risk reduction (heart rate compared to placebo: 0.93, 0.80 and 0.85 in the 50, 150 and 300 mg groups, respectively).^[@bibr3-2048004020929235]^ However, there is a clear relationship between reductions in inflammation and improved outcomes, as canakinumab exhibits no pharmacological effects that are not anti-inflammatory.

Ultimately, multiple processes contribute to the progression of atherosclerosis and the development of CVD. Effective treatment is likely to involve early and aggressive lipid-lowering and anti-inflammatory therapies, with CRP levels used to assess who is most likely to benefit from anti-inflammatory treatment. This research has shown for the first time that the magnitude of reduction in CRP achieved with therapies for atherosclerosis does not directly correlate to cardiovascular event reduction across clinical studies; however, there is a lack of data on treatments that reduce inflammation independent of cholesterol lowering. Further clinical studies of novel anti-inflammatory agents are necessary to expand on the efficacy observed during CANTOS.

In 2018, Ridker et al. reported that on-treatment CRP reduction after the first dose of canakinumab was predictive of clinical benefit during CANTOS when adjusted for baseline CRP and LDL cholesterol, but that baseline characteristics did not reliably predict efficacy.^[@bibr29-2048004020929235]^ This may support a future use of achieved CRP levels in the clinic to assess whether anti-inflammatory treatment should be continued, which is particularly relevant from a cost-effectiveness perspective. However, this research does not support the routine use of on-treatment CRP to assess response to current therapies.

One strength of this review is the inclusion of studies that measured hard clinical endpoints. Another related strength is the quality of the studies, with 80% receiving the highest quality grade, and no studies receiving the lowest grade. There are several important limitations. First, one reviewer screened and selected studies. The meta-analysis also included both primary and secondary prevention studies, which may have affected the outcome due to differing baseline characteristics. Inconsistent duration of follow-up may also have introduced variation.

Conclusion {#sec18-2048004020929235}
==========

This systematic review suggests that the magnitude of CRP reduction does not correlate with cardiovascular outcomes following treatment with therapies for atherosclerosis. Established risk factors LDL and triglycerides had a greater influence on changes in event rates than changes in CRP, with CRP reduction strongly associated with LDL reduction. Lipid targets should remain the primary focus for cardiovascular risk reduction, with on-treatment CRP most useful for patients with high levels of inflammation characteristic of severe atherosclerosis.
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Study (authors/title)Year publishedNumber of participantsType of studyInclusion criteriaInterventionComparatorPrimary endpointsNotesRidker et al.,^[@bibr3-2048004020929235]^ CANTOS201710,061dbRCTPrevious MI, hsCRP ≥2 mg/lCanakinumab 50, 100 and 150 mgPlaceboNonfatal MI, nonfatal stroke and CV mortalityRidker et al.,^[@bibr19-2048004020929235]^ JUPITER200817,802dbRCTNo CVD history, LDL-C \< 3.4 mmol/l and hsCRP ≥ 2 mg/lRosuvastatin 20 mgPlaceboFirst MACEWang et al.^[@bibr11-2048004020929235]^2016106RCTCHD + hyperlipidemiaEzetimibe 10 mg + rosuvastatin 10 mgRosuvastatin 10 mgNew/recurrent MI, unstable angina, CV mortality and strokeNicholls et al.,^[@bibr12-2048004020929235]^ SATURN20111039dbRCTOne vessel with \>20% stenosis + target vessel \<50% obstructedAtorvastatin 80 mgRosuvastatin 40 mgPercent change in atheroma volumeAlso measured MACERidker et al.,^[@bibr20-2048004020929235]^ AFCAPS/TexCAPS (substudy)20015742dbRCTAverage TC and LDL, below average HDLLovastatin 20 mg, adjusted to 40 mg as necessaryPlaceboFirst acute coronary eventHeljić et al.^[@bibr17-2048004020929235]^200995RCTT2DM without CHDSimvastatin 40 mgPlaceboAcute MI, revascularisation and strokeSever et al.,^[@bibr21-2048004020929235]^ ASCOT-LLA (substudy)20132772Randomised open-label, blinded-endpointHypertensive patients with 3+ CVD risk factors but no MI or angina historyAtorvastatin 10 mgPlaceboCV mortality, nonfatal MI, revascularisation and strokeYusuf et al.,^[@bibr23-2048004020929235]^ HOPE-3201612,705dbRCTAt least one CVD risk factor (men) or at least two (women)Rosuvastatin 10 mgPlaceboCV mortality, nonfatal MI, nonfatal stroke, cardiac arrest, HF, revascularisationSoedamah-Muthu et al.,^[@bibr22-2048004020929235]^ Collaborative Atorvastatin Diabetes Study20152322RCTT2DMAtorvastatin 10 mgPlaceboMACEWatanabe et al.,^[@bibr13-2048004020929235]^ CHERRY2017193Non-blinded RCTStable angina, PCIEicosapentaenoic acid 1800 mg + pitavastatin 4 mgPitavastatin 4 mgChange in coronary plaque tissue characteristicsAlso measured MACEIm et al.^[@bibr14-2048004020929235]^20182000dbRCTPCI within 12 months, aspirin monotherapyAtorvastatin 40 mgPravastatin 20 mgMACEKitas et al.,^[@bibr18-2048004020929235]^ TRACE-RA20193002dbRCTRAAtorvastatin 40 mgPlaceboMACETaguchi et al.,^[@bibr15-2048004020929235]^ REAL-CAD201813,054Randomised open-label, blinded-endpointStable CADPitavastatin 4 mgPitavastatin 1 mgCV mortality, nonfatal stroke, nonfatal MI, unstable anginaBhatt et al.,^[@bibr16-2048004020929235]^ REDUCE-IT20198179dbRCTEstablished CVD, diabetes or other risk factorsIcosapent ethyl 2 g twice dailyPlaceboMACEGilham et al.,^[@bibr24-2048004020929235]^ SUSTAIN/ASSURE2016499dbRCTStable CAD (SUSTAIN), coronary angiography (ASSURE)RVX-208 100 mg twice daily + SOCPlacebo + SOCMACE
